0001570562-24-000095.txt : 20240606 0001570562-24-000095.hdr.sgml : 20240606 20240606190124 ACCESSION NUMBER: 0001570562-24-000095 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240604 FILED AS OF DATE: 20240606 DATE AS OF CHANGE: 20240606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MOATAZEDI DAVID CENTRAL INDEX KEY: 0001700836 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38381 FILM NUMBER: 241026813 MAIL ADDRESS: STREET 1: C/O OBALON THERAPEUTICS, INC. STREET 2: 5421 AVENIDA ENCINAS, SUITE F CITY: CARLSBAD STATE: CA ZIP: 92008 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evolus, Inc. CENTRAL INDEX KEY: 0001570562 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461385614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 520 NEWPORT CENTER DRIVE STREET 2: SUITE 1200 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 BUSINESS PHONE: (949) 284-4555 MAIL ADDRESS: STREET 1: 520 NEWPORT CENTER DRIVE STREET 2: SUITE 1200 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 4 1 wk-form4_1717714876.xml FORM 4 X0508 4 2024-06-04 0 0001570562 Evolus, Inc. EOLS 0001700836 MOATAZEDI DAVID 520 NEWPORT CENTER DR. SUITE 1200 NEWPORT BEACH CA 92660 1 1 0 0 See Remarks 0 Common Stock 2024-06-04 4 S 0 140214 12.7283 D 533349 D Common Stock 2024-06-05 4 M 0 155278 5.46 A 688627 D Common Stock 2024-06-05 4 S 0 155278 12.9217 D 533349 D Common Stock 2024-06-06 4 M 0 175940 7.28 A 709289 D Common Stock 2024-06-06 4 S 0 175940 12.5866 D 533349 D Stock Option (Right to Buy) 5.46 2024-06-05 4 M 0 155278 0 D 2032-01-25 Common Stock 155278 155281 D Stock Option (Right to Buy) 7.28 2024-06-06 4 M 0 175940 0 D 2028-05-06 Common Stock 175940 1006079 D The shares were sold in multiple trades at prices ranging from $12.70 to $12.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares were sold in multiple trades at prices ranging from $12.77 to $13.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares were sold in multiple trades at prices ranging from $12.40 to $12.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares subject to the option vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. The shares subject to the option vested in full over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 6, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. CEO and President /s/ Jeffrey J. Plumer, as attorney-in-fact for David Moatazedi 2024-06-06